|
Volumn 368, Issue 9539, 2006, Pages 915-916
|
The Trivacan study
|
Author keywords
[No Author keywords available]
|
Indexed keywords
COTRIMOXAZOLE;
ZIDOVUDINE;
VIRUS RNA;
CD4 ANTIGEN;
ANTIMETABOLITE;
AFRICA;
CD4 LYMPHOCYTE COUNT;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LETTER;
PRIORITY JOURNAL;
PROPHYLAXIS;
THERAPY DELAY;
TREATMENT OUTCOME;
TREATMENT PLANNING;
DISEASE COURSE;
TREATMENT INTERRUPTION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DRUG ADMINISTRATION;
DRUG EFFECT;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
METHODOLOGY;
MULTICENTER STUDY;
NOTE;
RANDOMIZED CONTROLLED TRIAL;
ENTEROBACTER INFECTION;
ANTIGENS, CD4;
ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE;
DRUG ADMINISTRATION SCHEDULE;
HIV INFECTIONS;
HUMANS;
MULTICENTER STUDIES;
RANDOMIZED CONTROLLED TRIALS;
ANTIMETABOLITES;
ENTEROBACTERIACEAE INFECTIONS;
ZIDOVUDINE;
|
EID: 33748314788
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(06)69365-3 Document Type: Letter |
Times cited : (1)
|
References (5)
|